Sarepta Therapeutics spikes 57% after a key trial shows its experimental gene therapy worked in 3 patients (SRPT, SLDB)

Sarepta Therapeutics was up more than 57% Tuesday morning after a key trial showed its experimental gene therapy worked in three patients. Follow Sarepta Therapeutics in real time here. Sarepta on Tuesday announced positive results for an early trial of three patients with duchenne muscular dystrophy who were given a gene therapy. After receiving the therapy, three boys, under the age of six, saw an increase in the protein.